This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Zacks News
Nurix Therapeutics, Inc. (NRIX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Nurix Therapeutics (NRIX) delivered earnings and revenue surprises of 5% and 13.77%, respectively, for the quarter ended February 2024. Do the numbers hold clues to what lies ahead for the stock?
IGM Biosciences, Inc. (IGMS) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
IGM Biosciences, Inc. (IGMS) delivered earnings and revenue surprises of 4.72% and 31.47%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Wall Street Analysts Think IGM Biosciences, Inc. (IGMS) Could Surge 63.1%: Read This Before Placing a Bet
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 63.1% in IGM Biosciences, Inc. (IGMS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Strength Seen in iTeos Therapeutics, Inc. (ITOS): Can Its 7.4% Jump Turn into More Strength?
by Zacks Equity Research
iTeos Therapeutics, Inc. (ITOS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Wall Street Analysts Believe IGM Biosciences, Inc. (IGMS) Could Rally 35.08%: Here's is How to Trade
by Zacks Equity Research
The consensus price target hints at a 35.1% upside potential for IGM Biosciences, Inc. (IGMS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
IGM Bio (IGMS) Stock Rallies 142% in 3 Months: Here's Why
by Zacks Equity Research
IGM Bio (IGMS) stock surges 142% in the past three months on strategic reprioritization efforts to focus its resources on the development of pipeline candidates for cancer and autoimmune indications.
Does IGM Biosciences, Inc. (IGMS) Have the Potential to Rally 268.31% as Wall Street Analysts Expect?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 268.3% in IGM Biosciences, Inc. (IGMS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Orchard Therapeutics PLC Sponsored ADR (ORTX) Soars 12.9%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Orchard Therapeutics PLC Sponsored ADR (ORTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
IGM Biosciences, Inc. (IGMS) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
IGM Biosciences, Inc. (IGMS) delivered earnings and revenue surprises of 0% and 37.43%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in IGM Biosciences, Inc. (IGMS): Can Its 7.6% Jump Turn into More Strength?
by Zacks Equity Research
IGM Biosciences, Inc. (IGMS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
IGM Biosciences, Inc. (IGMS) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
IGM Biosciences, Inc. (IGMS) delivered earnings and revenue surprises of 2.92% and 70.89%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
IGM Biosciences, Inc. (IGMS) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
IGM Biosciences, Inc. (IGMS) delivered earnings and revenue surprises of 22.22% and 0.80%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
IGM Biosciences, Inc. (IGMS) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
IGM Biosciences, Inc. (IGMS) delivered earnings and revenue surprises of 8.97% and 15.13%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
IGM Biosciences, Inc. (IGMS) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
IGM Biosciences, Inc. (IGMS) delivered earnings and revenue surprises of 7.64% and 99.32%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Biotech Stock Roundup: AXSM to Acquire JAZZ's Drug, IGMS Up on SNY Deal & More
by Zacks Equity Research
Acquisition and collaboration news from Axsome (AXSM) and IGM Biosciences, Inc. (IGMS), respectively, are a few key highlights from the biotech sector during the past week.
IGM (IGMS) Skyrockets on Collaboration Deal With Sanofi
by Zacks Equity Research
IGM Biosciences (IGMS) inks a deal with Sanofi (SNY) to discover and develop new therapies based on its proprietary technology, which is set to target oncology, immunology and inflammation targets.
Here's Why IGM Biosciences, Inc. (IGMS) is Poised for a Turnaround After Losing 50.6% in 4 Weeks
by Zacks Equity Research
IGM Biosciences, Inc. (IGMS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
IGM Biosciences (IGMS) Catches Eye: Stock Jumps 8.7%
by Zacks Equity Research
IGM Biosciences (IGMS) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.